Efgartigimod: A Review in Generalised Myasthenia Gravis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis.CNS drugs · 2026
   Review
2. Assessing Efgartigimod (VYVGART™) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional Sentiments.Neurology and therapy · 2026
   Article
3. Efgartigimod as adjunctive therapy in refractory autoimmune glial fibrillary acidic protein astrocytopathy: a case series.Journal of neurology · 2026
   Article
4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.Brain and behavior · 2026
   Review
5. Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Review
6. Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis.Cureus · 2026
   Article
7. Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.Frontiers in immunology · 2026
   Observational
8. Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
   Article
9. Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.Therapeutic advances in neurological disorders · 2026
   Article
10. Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.CNS neuroscience & therapeutics · 2025
    Article
11. Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.Frontiers in immunology · 2025
    Article
12. The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial.Frontiers in immunology · 2025
    Article
13. Case Report: Guillain-Barré syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment.Frontiers in immunology · 2025
    Article
14. An Unusual Presentation of Bullous Skin Lesions During Pregnancy.Journal of investigative medicine high impact case reports
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as